Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial

Abstract:Early initiation of antiretroviral treatment (ART) reduces HIV transmission and has health benefits. HIV drug resistance can limit treatment options and compromise use of ART for HIV prevention. We evaluated drug resistance in 85 participants in the HIV Prevention Trials Network 052 trial who started ART at CD4 counts of 350–550 cells per cubic millimeter and failed ART by May 2011; 8.2% had baseline resistance and 35.3% had resistance at ART failure. High baseline viral load and less education were associated with emergence of resistance at ART failure. Resistance at ART failure was observed in 7 of 8 (87.5%) participants who started ART at lower CD4 cell counts.

[1]  P. Harrigan,et al.  Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes , 2015, AIDS.

[2]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[3]  R. Salamon,et al.  A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. , 2015, The New England journal of medicine.

[4]  M. Reitsma,et al.  Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  J. Snowden,et al.  Monitoring of chimerism following allogeneic haematopoietic stem cell transplantation (HSCT): Technical recommendations for the use of Short Tandem Repeat (STR) based techniques, on behalf of the United Kingdom National External Quality Assessment Service for Leucocyte Immunophenotyping Chimerism Wo , 2015, British journal of haematology.

[6]  Kenneth H Mayer,et al.  Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. , 2014, The Lancet. Infectious diseases.

[7]  R. Piso.  Can we trust the guidelines? Comparison between the data presented and the recommendations of the International Antiviral Society-USA Panel. , 2014, Journal of the International AIDS Society.

[8]  C. Delaugerre,et al.  French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults , 2014, Journal of the International AIDS Society.

[9]  K. Mayer,et al.  Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). , 2013, The Journal of infectious diseases.

[10]  Anne M Johnson,et al.  Role of HIV Infection Duration and CD4 Cell Level at Initiation of Combination Anti-Retroviral Therapy on Risk of Failure , 2013, PloS one.

[11]  Michael Rayment,et al.  Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.

[12]  T. F. Rinke de Wit,et al.  Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  H. Bang,et al.  Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. , 2010, The New England journal of medicine.

[14]  C. Armon,et al.  Initiation of HAART at Higher CD4 Cell Counts Is Associated With a Lower Frequency of Antiretroviral Drug Resistance Mutations at Virologic Failure , 2009, Journal of acquired immune deficiency syndromes.

[15]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .

[16]  B. Walker,et al.  Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Christopher D Pilcher,et al.  Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. , 2006, JAMA.

[18]  Tommy F. Liu,et al.  Web resources for HIV type 1 genotypic-resistance test interpretation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  P. Harrigan,et al.  Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. , 2005, The Journal of infectious diseases.

[20]  J. Bremer,et al.  Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories , 1992, Journal of clinical microbiology.

[21]  Huldrych F. Günthard,et al.  Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. , 2012, JAMA.

[22]  Douglas D. Richman,et al.  Antiretroviral Treatment of Adult HIV Infection , 2008 .